| Document Date: 2011-11-05 11:55:33
Open Document File Size: 165,96 KBShare Result on Facebook
City San Francisco / Hoersholm / Frankfurt / San Diego / / Company Enzon Pharmaceuticals / Santaris Pharma A/S / Pfizer / GlaxoSmithKline / Shire plc / Mitchell AE / miRagen Therapeutics / Global Communications Santaris Pharma A/S / / Continent Europe / / Country Germany / Netherlands / United States / Denmark / / Currency pence / USD / / / Event FDA Phase / / Facility Institute of Medicine / Erasmus MC University Hospital / JW Goethe University Hospital / / IndustryTerm pharmaceutical / biopharmaceutical / / MedicalCondition infectious / Hepatitis C / hepatitis B / liver cirrhosis / hepatitis / chronic HCV infection / infections / HCV genotype / cancer / disease / Liver Diseases / cardiovascular disease / HCV / viral disease / liver cancer / diseases / infectious diseases / infection / inflammation / chronic Hepatitis C / inflammatory / disorders / HCV RNA / / Organization Liver Unit / World Health Organization / Department of Medicine / JW Goethe University Hospital / MC University Hospital Rotterdam / / Person Harry Janssen / Stefan Zeuzem / Michael R. Hodges / / / Position Professor of Medicine and Chief / Lead Clinical Investigator / Head / Officer / Director / Major / Vice President and Chief / / Product LNA / ribavirin / miravirsen / / ProvinceOrState California / / Technology siRNA technologies / pdf / Drug Discovery / gene expression / genotype / drug development / / URL www.santaris.com / http /
SocialTag |
Santaris Pharma A/S Phase 2a data of miravirsen shows dose-dependent, prolonged viral reduction of 2-3 logs HCV RNA after four-week treatment in Hepatitis C patients -- New Phase 2a clinical data to be presented in late-breaking oral presentation at AASLD –